We came upon the article titled “The Role of Medications in Causing Dry Eye” [1], during a recent literature search conducted for a continuing education program we recently produced on the management of dry eye disease.

In reviewing this article, we noted a number of errors, particularly in Tables 3 and 4. Specifically, many of the drugs are misclassified and/or allocated to incorrect therapeutic drug classes, and accordingly, corrigendum has been published.

Please also note the following errors:(i)Anti-arrhythmic was misspelled in the publication (“antiarrythmic”)(ii)Hyoscine methobromide was listed as an alternate name for methscopolamine, but these two agents are not equivalent(iii)Chlorthalidone was misspelled in the publication (“chlortalidone”)

Please also note that we did not review the literature behind the drugs listed under “drugs secreted in tears” and are therefore unable to validate these claims.

While we do not question the likelihood that these medications may cause or aggravate dry eye, the fact that they are not appropriately classified or identified may lead to unintentional errors or misconceptions by practitioners, students, or patients not familiar with these medications.

As this article has been cited by a number of other papers in the relevant literature, we appreciate your attention to the content updates provided.

Our project focuses on interprofessional collaboration between pharmacists and eye care professionals, and in that spirit, we hope that this information is of value to you.

The list of our findings is presented in Table 3.

The list of our findings is presented in Table 4.

Conflicts of Interest

The authors declare that they have no conflicts of interest.